Table 1.

Results of PET Studies in Cases 1 and 2 Compared with Normal and Sporadic PD Controls

		PET results*
Measure	Location	Normal controls† (n=33)	sPD controls† (n=67)	Sagamihara family members
				Case 1	Case 2
Kocc, min−1	Caudate nucleus	0.0116±0.0010	0.0085±0.0017 (74%)	0.0055 (47%)	0.0070 (60%)
	Putamen	0.0104±0.0011	0.0046±0.0017 (44%)	0.0027 (26%)	0.0036 (35%)
BP (DTBZ)	Caudate nucleus	0.967±0.008	0.539 (56%)	0.41 (42%)	0.44 (45%)
	Putamen	0.979±0.009	0.353 (36%)	0.20 (20%)	0.21 (21%)
BP (MP)	Caudate nucleus	1.460±0.002	0.848±0.252 (58%)	0.43 (37%)‡	0.45 (39%)‡
	Putamen	1.319±0.002	0.490±0.236 (37%)	0.23 (26%)‡	0.25 (27%)‡
BP (RAC)	Caudate nucleus	2.28±0.24§	2.08±0.32//	2.89	2.59
	Putamen	2.27±0.27	2.39±0.4	3.11	2.84

BP, binding potential; DTBZ, ¹¹C-α-dihydrotetrabenazine; K_occ, uptake rate constant of ¹⁸F-6-fluoro-L-dopa; MP, ¹¹C-d-threo-methylphenidate; PD, Parkinson disease; RAC, ¹¹C-raclopride; sPD, sporadic PD.

^*Values shown are mean±SD or value (% of normal) for each tracer.

^†Data from Adams et al (8), except for BP (RAC), which are unpublished data (normal controls) and from de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu J-Q, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 2004;127:2747–54 (sPD controls).

^‡Age-adjusted.

^§N=10. Mean±SD age, 51.3±16.4 y.

^//N=8. Mean±SD age, 64.4±11.2 y.